We used the intestinal segregated flow model (SFM) versus the traditional model (TM), nested within physiologically based pharmacokinetic (PBPK) models, to describe the biliary and urinary excretion of morphine 3b-glucuronide (MG) after intravenous and intraduodenal dosing of morphine in rats in vivo. The SFM model describes a partial (5%-30%) intestinal blood flow perfusing the transporter-and enzyme-rich enterocyte region, whereas the TM describes 100% flow perfusing the intestine as a whole. For the SFM, drugs entering from the circulation are expected to be metabolized to lesser extents by the intestine due to the segregated flow, reflecting the phenomenon of shunting and route-dependent intestinal metabolism. The poor permeability of MG crossing the liver or intestinal basolateral membranes mandates that most of MG that is excreted into bile is hepatically formed, whereas MG that is excreted into urine originates from both intestine and liver metabolism, since MG is effluxed back to blood. was better predicted by the SFM-PBPK (2.59 at 4 hours) and not the TM-PBPK (1.0), supporting the view that the SFM is superior for the description of intestinal-liver metabolism of morphine to MG. The SFM-PBPK model predicts an appreciable contribution of the intestine to first pass M metabolism.
Introduction
It has been recognized that, generally, compartmental modeling is unable to quantitatively address the multiplicity of metabolite formation organs and does not account for sequential metabolism/excretion nor permeability barriers of formed metabolites (Pang et al., 2008; Pang, 2009) . In contrast, physiologically based pharmacokinetic (PBPK) models address events of sequential elimination and include transmembrane barriers Pang, 1986, 1993; Pang, 2003; Pang et al., 2009; Chow and Pang, 2013) and transporters (Sun et al., 2006 . The intestine, richly endowed with enzymes and transporters (van Herwaarden et al., 2007; Zhang et al., 2007 Zhang et al., , 2009 Liu et al., 2010) , strongly affects firstpass metabolism and controls the flow of substrate to the liver (Pang and Chow, 2012) . Intestinally formed metabolites may undergo immediate sequential metabolism or excretion (Pang and Gillette, 1979) . When the metabolite possesses good permeability or transporter-linked properties, it will cross the liver cell membrane to endure liver metabolism and/or biliary excretion prior to reaching the lung, heart, and general circulation.
Route-dependent metabolism by the intestine is repeatedly being observed (namely, a higher extent of intestinal metabolism exists when a drug is given orally versus the lower extent or virtual absence of intestine metabolism when the drug is given systemically) (Cong et al., 2000; Doherty and Pang, 2000; Fan et al., 2010) . This was observed for erythromycin (Lown et al., 1995) and midazolam (Paine et al., 1996) in humans and for enalapril hydrolysis (Pang et al., 1985) and morphine glucuronidation in the rat intestine . The lesser extent of intestinal metabolism for systemically delivered drugs is explained by the pattern that a fraction and not the entire intestinal blood flow perfuses and recruits enzymes/excretory transporters in the enterocyte region, with the majority of flow perfusing the inactive, serosal region (Cong et al., 2000; Fan et al., 2010) . These observations led to the development of the segregated flow model (SFM), describing that only a partial intestinal flow (5%-30%) reaches the enterocyte region to explain the higher oral versus intravenous intestinal metabolism. In contrast, the traditional model (TM) describes no difference, when the entire intestinal flow perfuses the intestinal tissue as a whole (Cong et al., 2000) .
In this study, we examined morphine glucuronidation in the rat in vivo after administration of small doses of natural (2)-morphine (M) in saline into the jugular vein for intravenous or duodenal lumen [or intraduodenal (ID)] dosing, with continuous bile collection via a catheter. We studied M, which enters the cell by passive diffusion (Doherty et al., 2006) and is primarily glucuronidated at the 3-position to form morphine 3b-glucuronide (MG) by the rat UDP-glucuronosyltransferase 2 family, polypeptide b1, Ugt2b1, in the rat intestine and liver (Rane et al., 1985) . Morphine is also known to be metabolized by cytochrome P450 (Projean et al., 2003) and undergoes excretion via P-glycoprotein (Böerner 1975; Iwamoto and Klaassen, 1977; Letrent et al., 1999; Wandel et al., 2002) to minor extents. The rat kidney actively secretes but does not metabolize M (Van Crugten et al., 1991; Shanahan et al., 1997) . MG is excreted from formation tissues; enterohepatic circulation in rats has been noted (Dahlström and Paalzow, 1978; Horton and Pollack, 1991) but not for the rat with an open bile fistula. The influx permeability clearance of MG through the liver (0.1 ml·min 21 ·g 21 liver) was estimated to be 5%-10% of the flow rate, suggesting the existence of a diffusional barrier for MG to enter the hepatocyte (Doherty et al., 2006) . Intestinally formed MG undergoes luminal secretion via the multiple drug resistance-associated protein 2 (Mrp2) and is effluxed into the circulation via the multiple drug resistance-associated protein 3 (Mrp3), in the rat (van de Wetering et al., 2007) . MG formed in the liver is biliarily excreted as well as effluxed out. These MG species of intestinal and hepatic origins that reenter the circulation are excreted by the kidney, with clearance (CL) values that are similar to the glomerular filtration rate (Van Crugten et al., 1991) . Intuitively speaking, the extents of intestine versus liver formation of MG, reflected by their appearance in urine/bile, should remain the same for both intravenous and intraduodenal dosing, when the flow patterns for the delivery of M to the intestine and liver are the same for different routes of drug administration, as with the TM model. By contrast, when M in the systemic circulation is being partially shunted away from the enterocyte for metabolism with intravenous dosing for the SFM model, the urine/bile ratio of MG for intravenous dosing of M is expected to be lower than that for intraduodenal dosing. The different extents of excretion of MG in bile versus urine for intraduodenal versus intravenous dosing of M could be used to appraise which intestine model, TM or SFM, best describes first-pass metabolism when nested within PBPK models.
Materials and Methods

Materials
M and MG were provided by the National Institutes of Health National Institute on Drug Abuse (Rockville, MD); caffeine, the internal standard (IS), was purchased from Sigma-Aldrich Co. (St. Louis, MO). High-performance liquid chromatography (LC)-grade acetonitrile, methanol, and formic acid were obtained from Fisher Scientific Canada (Ottawa, ON, Canada). Male SpragueDawley rats (St. Constant, QC, Canada), weighing 305 6 10 g (aged 8 to 9 weeks), were used throughout the study.
In Vivo Pharmacokinetic Study
Rats were maintained under constant housing and environmental conditions (temperature, lighting, and diet) according to protocols approved by the University of Toronto. Rats were abstained from food but were given 5% (w/v) glucose water overnight before the day of the study. Pentobarbital (65 mg·kg 21 , given intraperitoneally) was used to induce anesthesia, since ketamine was previously reported to inhibit morphine glucuronidation (Qi et al., 2010) . Under anesthesia, the carotid artery was cannulated with PE50 tubing, which was prefilled with heparinized (1000 U/ml) physiologic saline solution for sampling; the contralateral jugular vein was cannulated for the intravenous administration of M (Hirayama et al., 1990) . The intraduodenal dose solution was introduced as a bolus needle injection into the proximal duodenum. A midline incision was made for bile duct cannulation with PE50 tubing. The opened neck and abdominal regions for the surgical manipulations were sutured immediately after drug administration. For intravenous administration, M (expressed as morphine base, 14.961.6 mmol·kg 21 in 0.2 ml saline solution) was administered as a bolus into the jugular vein, followed by flushing of the inline contents with saline. For intraduodenal administration, morphine sulfate (expressed as M, 26.6 6 0.40 mmol·kg 21 in 0.3 ml saline solution) was injected into the proximal duodenal lumen.
The difference in weights of the syringe before and after the injection was taken as the volume of dose injected, and the dose solution was assayed by LC/mass spectrometry. Blood (0.1 ml) was collected via the carotid artery cannula of the same rat at 0, 1, 5, 10, 15, 30, 45, 60, 90, 120, 180 , and 240 minutes after dosing for each rat. Bile was collected in toto via the bile duct cannula at 0, 5, 10, 15, 20, 30, 45, 60, 90, 180 , and 240 minutes after dosing into prepared 1.5-ml vials. At the end of study (240 minutes), the entire urinary content was collected from the bladder via sampling with a needle/syringe. All samples were kept frozen at 220°C until analysis.
LC/Mass Spectrometry Assay
Protein Precipitation and Solid Phase Extraction. A set of standards of known, added amounts of M and MG in blood was processed in the same manner as the samples. Caffeine (IS; 10 ml of 3 mg·ml
21
) was added to 100 ml blood, followed by protein precipitation with 400 ml of an equimixture of methanol and acetonitrile, which was found to yield the highest recovery of the compounds. After vortex mixing for 60 seconds and centrifugation at 13,000g for 10 minutes, the supernatant was transferred into Sep-Pak Vac C 18 3-cc cartridges (200 mg; Waters, Milford, MA). Each cartridge was preconditioned with 2 Â 1 ml acetonitrile followed by 2 Â 1 ml Millipore water (Millipore, Billerica, MA). After loading of sample, 0.5 ml 5% acetonitrile in water was added into the cartridge and the contents in the cartridge were eluted with 2 Â 1 ml acetonitrile. The eluent was pooled and dried under N 2 at room temperature. The residue was reconstituted with 200 ml mobile phase [70% water with 0.1% (v/v) formic acid and 30% acetonitrile with 0.1% (v/v) formic acid], and 5 ml reconstituted sample was injected into the LC-MS/MS system. Calibration curves for the quantification of M and MG in bile and urine samples were constructed under identical conditions. Because of the differential abundances of MG and M in bile, 10 ml bile (for MG assay) and 40 ml bile (for morphine assay) was assayed in separate runs. Samples were spiked with 5 or 10 ml IS solution, then diluted with saline to 100 ml, before mixing with 400 ml methanol and acetonitrile [1:1 (v/v)] for solid phase extraction loading. For urine analysis, 10 ml of the urine sample was spiked with 10 ml IS solution and diluted to 100 ml with saline, then mixed with 400 ml methanol and acetonitrile [1:1 (v/v)] for solid phase extraction loading. These samples were then processed identically to that described for the blood samples.
LC-MS/MS. LC-MS/MS was composed of an Agilent 1200 series liquid chromatograph coupled to an Agilent 6410 triple-quadrupole mass spectrometer with an electrospray source (Agilent Technologies, Santa Clara, CA). A highperformance LC gradient consisting of the mobile phase components of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B), increasing from 4% to 30% between 5 and 10 minutes, then returning to 4% over the next minute, was developed to separate MG, morphine, and caffeine (IS) at retention times of 2.6, 4.3, and 10.9 minutes, respectively. Transitions from precursor ion to product ion were observed with multiple reaction monitoring, as shown with the respective mass-to-charge ratio (m/z): MG (m/z 462 → 286), morphine (m/z 286.1 → 165), and caffeine (m/z 195 → 138). Values for fragments or voltage and collision energy were 160 V and 32 V for MG, 165 V and 40 V for M, and 85 V and 24 V for caffeine, respectively. The area of each peak, obtained by MassHunter workstation software (Agilent Technologies), was normalized to that of the IS. A good correlation that showed linearity (R 2 . 0.997) between the added compound/IS area ratio versus the amount of compound in the sample (blood/bile/urine) was observed. The coefficient of variation (CV) was , 14% for all of the concentrations studied. The intraday CV was between 0.4% and 9.2% for M concentrations ranging between 20 and 2470 ng·ml 21 and between 0.9% and 12.9% for MG for concentrations ranging between 16 and 2390 ng·ml
. The data showed good linearity for the blood (R 2 . 0.997), urine (R 2 . 0.98), and bile (R 2 . 0.98) calibration curves, and the limit of quantification was 9.75 and 19.5 ng·ml 21 for morphine and MG, respectively.
Data Analysis
Noncompartmental/Compartmental Analyses. The total area under the concentration-time curve (AUC) to infinity was estimated as the sum of AUC 0-t , obtained with the trapezoidal rule, and AUC extrap , obtained by dividing the blood 1124 Yang et al. at ASPET Journals on January 20, 2018 dmd.aspetjournals.org Downloaded from concentration of the last sampling point (C last ) by b, the terminal slope. The total body (blood) clearance (CL tot ) was calculated as Dose IV /AUC ',IV . The bioavailability (or F sys ) was calculated from the dose-normalized AUC ',ID /AUC ',IV or approximated by the amounts of M excreted into urine at 4 hours after intraduodenal/intravenous dosing. Concentration and amount data were normalized to dose, and data were expressed means 6 S.D.
A two-compartment model for M and a one-compartment model for MG were used for compartmental analysis and fitting of M and MG data (Fig. 1) . The total elimination rate constant of M arising from the central compartment (k 10 ) comprises the metabolic (k m ), biliary (k bile ), and renal (k renal ) excretion rate constants and k m,others for other metabolic pathways; k a , k 12 , and k 21 denote the absorption and intercompartmental rate constants, respectively; and V 1 and F abs are the central volume of distribution and fraction of dose absorbed, respectively. The metabolite, MG, with volume of distribution V{mi}, is excreted into bile and urine, with rate constants k{mi} bile and k{mi} renal , respectively.
PBPK Models. The TM-PBPK and SFM-PBPK models (Fig. 2) were used for optimization of the intravenous and intraduodenal blood, bile and urine data of M and MG. Five tissues were considered: rapidly perfused (RP) tissue, poorly perfused (PP) tissue, and adipose (AD) tissue, liver (L), and intestine (I), which are denoted as subscripts and interconnected by blood flow (Q). For detailed consideration of first-pass metabolism of M, the liver and intestinal tissues were subcompartmentalized as the tissue and tissue blood compartments to better accommodate the permeability barrier of MG. M in intestinal blood (IB) and liver blood (LB) rapidly exchanges with those in tissue with influx (CL and CL MG R , respectively. For the SFM, the intestine tissue is further subdivided into the enterocyte (en) and serosal (s) regions and the corresponding blood regions (enB and sB); the enterocyte flow, Q en , perfusing the metabolically active and transporterrich region is only a small fraction (f Q = 0.05 to 0.3) of the total intestinal flow rate, Q I or Q PV ; the serosal flow, Q s , is (1 2 f Q ) Q I ( Fig. 2B) (Cong et al., 2000) .
Fitting. Fitting was conducted by ADAPT 5 Systems Analysis Software (BMSR Biomedical Simulations Resource, version 5; University of Southern California, Los Angeles, CA). The population method and the maximum likelihood with the Expectation-Maximization (EM) algorithm were used to fit individual sets of data (intravenous, n = 4; intraduodenal, n = 3) and the population data set that is based on individual data sets. We employed a two-compartment model for M and a one-compartment model for the metabolite, MG, to fit individual data sets (data for each rat) and all of the data as a whole (Fig. 1) . Fitted results furnished estimates of k a , total elimination (k 10 ), k m , k bile , k renal , k m,others , k 12 , k 21 , V 1 , and F abs , with rate equations shown in Appendix A.
Then the TM-PBPK and SFM-PBPK models ( were first assigned as 5Â flow to tissue; the tissue to blood partitioning coefficients of M for the rapidly perfused tissue (K RP ), poorly perfused tissue (K PP ), and adipose tissue (K AD ), calculated according to Rowland (2006, 2007) , were used as initial estimates (Table 2 ) and the parameters were optimized by fitting. Similar K T values for MG were not needed since transport terms were used for the intestine and liver, the few tissues where MG was distributed. The equations, assumptions, and mass balance equations are shown in Appendix B. Only the unbound species was involved in transport and elimination; the unbound fraction in plasma (f P ) was corrected by the blood/plasma concentration ratio (C B /C P ) to obtain the unbound fraction in blood, f B . The tissue unbound fraction (f T ) and the intrinsic metabolic or transport clearance were estimated as a combined parameter. All of the intrinsic clearances for metabolism (CL int,met ) and secretion (CL int,sec ) for the intestine (I) and liver (L), as well as the rate constants for absorption (k a ), and fraction of dose absorbed in gut lumen (F abs ), were obtained by fitting. F abs is the ratio of k a /(k a +k g ) where k g is the luminal degradation rate constant.
We also fitted the data with the nested TM-and SFM-PBPK models. With the fitted constants, simulations were extended to time infinity to estimate the amounts of MG in bile and urine for the TM-or SFM-intestine compartment nested in the PBPK model. Ratios of amounts of MG excreted into urine and bile after intraduodenal and intravenous dosing of M were then compared for the TM and SFM-PBPK models. The final model was selected based on the goodness-offit criteria, which included convergence, parameter precision, and visual inspection of predicted versus observed values and residual plots. The sum of squared residuals, CV (or standard deviation of fitted parameter/parameter estimate), residual plots, as well as the F test were used to compare goodness of fit of the nested TM-and SFM-PBPK models (Boxenbaum et al., 1974) .
Mass Balance Solutions for M and MG Amounts in Bile and Urine. Simple mass balance considerations were developed to illustrate the relationship between the intestine and liver in forming the metabolite in question. It was assumed that the intestine and liver are the only two organs capable of forming MG, and M is completely absorbed. For simplification, MG is assumed as unable to enter the intestine or liver. Mass balance relations involving the intestinal and hepatic availabilities/extraction ratios of M and MG, the formed metabolite, are included to describe the formation of MG by the intestine and liver and in the sequential removal of MG.
Statistical Comparisons
The two-tailed t test was used to compare the means, and a P value of , 0.05 was viewed as significant.
Results
In Vivo Pharmacokinetics of M after Intravenous and Intraduodenal Dosing to Rats: Noncompartmental Analysis M decayed biexponentially after intravenous dosing, although the biphasic profile was not apparent after intraduodenal dosing (Fig. 3) . The terminal half-lives for M, estimated by regression of log-linear portion of decay curves, were identical for intraduodenal and intravenous dosing (61 and 67 minutes; P . 0.05). The area under the blood concentrationtime curve for M (AUC ',IV ), obtained by summing the AUC by the trapezoidal rule and extrapolated area (C last /b), yielded a total body blood clearance (CL tot ) of 6.6 6 3.3 ml·min
21
, a value comparable to the blood clearance of 6.31 ml·min 21 [CL P /(C B /C P ) according to Mistry and Houston (1987) , based on plasma clearance, CL P , of 8.46 and a C B /C P ratio of 1.34]. Both M and MG were recovered in bile and urine in different proportions ( Fig. 3 ; Table 3 ). The renal clearance of M, , 1997) . The bioavailability (F sys ) estimated according to the dose-corrected AUC ',ID / AUC ',IV and intraduodenal/intravenous ratio of amounts of morphine recovered in urine at 4 hours were 0.229 and 0.215, respectively (Table 3) . These values are lower than that (0.36) from Mistry and Houston (1987) but slightly higher than those reported by Iwamoto and Klaassen (1977) and Dahlström and Paalzow (1978) (0.14 and 0.15, respectively).
MG appeared rapidly in blood, and the terminal half-lives (79 and 72 minutes) of decay of MG from intravenous and intraduodenal dosing of M were slightly but insignificantly longer than those for M (P . 0.05, paired t; at 4 hours after dosing (Table 3) .
Compartmental Modeling of M and MG
Fitting of the blood concentration-time profiles of M and MG after intravenous and intraduodenal dosing was generally satisfactory for both routes of administration (Fig. 3) . However, MG in bile was overestimated for intravenous data but underestimated for intraduodenal data, whereas MG in urine was overpredicted for intravenous dosing but underpredicted for intraduodenal dosing. The AUCs provided an estimate of 0.95 for F abs that was higher than observed. The calculated, total clearance (k 10 V 1 ) was 0.0711 * 140 or 9.95 ml·min 21 (Table 4 ) and was higher than that observed (Table 3) . According to the ratio of each rate constant/k 10 , the pathways for formation of other metabolites (1.4%), biliary excretion (less than 1%), and renal excretion (31%) contributed much less to the total elimination compared with the glucuronidation pathway (67.5%) or k m /k 10 .
SFM-PBPK and TM-PBPK Modeling of M and MG
The tissue/blood concentration ratios, or the tissue partitioning ratios were calculated based on the methods of Rowland (2006, 2007) with use of known fractional volumes of the intracellular and extracellular tissue water, neutral lipid and phospholipid, and concentration of binding elements: extracellular albumin, acidic phospholipids, and neutral lipids and phospholipids; the pKa and the oil to water partition coefficient, P o/w , for octanol/water and vegetable oil/water were used in the calculation. These were compared with the optimized tissue to blood partitioning coefficients (K T ) that were estimated by fitting (Table 2) . Generally, the fitted estimates were within 62-fold of the calculated values of K RP , K PP , and K AD .
The fits to the PBPK models were much improved compared with that from compartmental fitting (compare Figs. 3 and 4 ; Table 6 ). The blood levels of MG were less well predicted by the TM than for the SFM; MG appearance was overestimated in bile both after intravenous and intraduodenal dosing but was underestimated in urine after intraduodenal dosing by TM. Pictorially, predictions by the SFM-PBPK model provided data that closely matched the observed, temporal data for concentration, bile, and urinary profiles up to the 4 hours, compared with the TM (Fig. 4) . The fitted parameters of the SFM-PBPK and TM-PBPK are summarized in Table 5 . The predicted versus observed data (Figs. 5 and 6) showed that the SFM-PBPK model fitted the data better than the TM-PBPK model. The F test showed that the SFM-PBPK provided the best fits over those for the TM-PBPK and compartmental models (Table 6) .
Additional parameters were obtained from PBPK modeling ( Table 7) . The apparent (unbound) tissue to blood partitioning ratios of M, obtained
, are 0.14 to 0.53 for the intestine respectively. We also estimated F I and F L according to the equations of , shown below. was 0.12 to 0.22 for the liver for the TM-and SFM-PBPK models. The data showed little extraction of MG by the intestine but substantial extraction of MG by the liver, according to the TM-and SFM-PBPK models, respectively. The fraction of hepatic clearance of M forming MG, or h mi , was obtained as the ratio of the formation intrinsic clearance/ total intrinsic clearance, or . 85% for both the TM-and SFM-PBPK models, showing that glucuronidation is a major elimination pathway in the liver. The fraction of total body clearance of M forming MG, g mi , was around 57%-63%, a value similar to the estimate from the compartmental model. The value is lower since M is excreted unchanged into urine. The fractional contributions of the intestine and liver to the first-pass removal were estimated. The extents of intestine and liver removal of M are highly dependent on f Q , the fractional enterocyte flow (Pang and Chow, 2012 ) (eqs. 1 and 2): Obtained from Peters (2008) , based on 60% of intestine volume. d Obtained from Everett et al. (1956) , based on liver weight of 12.1 g, according to Davies and Morris (1993) . Calculated according to the method of Rowland (2006, 2007) . d Fitted estimates, with percent CV within parentheses.
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The percent contribution by the intestine was 46%-57% and 9.3%-17% for the TM-PBPK and SFM-PBPK models, respectively; the percent contribution by the liver was 43%-54% and 83%-91% for the TM-PBPK for SFM-PBPK models, respectively (Table 7) . These values differed due to the two methods for estimating F I and F L . The data for the SFM-PBPK model were closer to the observations than those for the TM-PBPK (Table 8) . These values were not changed dramatically upon extrapolation of the data to infinity.
Mass Balance Solutions for TM-PBPK versus SFM-PBPK
We also probed the mass balance relations for the TM versus the SFM. In this examination, several assumptions were made so that meaningful relations could be obtained easily: M is completely absorbed for the intraduodenal dose (F abs = 1) but there is no enterohepatic recirculation for M secreted back to the lumen; M only forms MG and not other metabolites in the intestine and liver. These assumptions are quite reasonable in view of the fitted results (Tables 5 and 7) . We further included renal excretion of M, with f e to define the fraction of the intravenous dose of M excreted unchanged. The most important assumption was that MG in the systemic circulation does not enter the intestine or liver but is renally excreted.
TM-PBPK
According to the TM-PBPK, the serial blood circuit delivering M and MG to the enterocyte (or whole intestine) region and the liver remains unchanged for both intravenous and intraduodenal dosing. The intestine exerts its strategic, anterior placement over the liver in its initial removal of substrates before the species reach the liver. The extent of MG formation by both the intestine and liver is given by (E I + F I E H ). Thus, the percent contribution to MG formulation during the first pass by the intestine and liver is
respectively. These fractions, when multiplied by the organappropriate available fractions for MG, Ffmig I , and Ffmig L for the formed metabolite, yield the extents of formed MG entering the circulation "
For the intestine and liver, the portions of the MG formed that are immediately excreted into the gut lumen and bile, respectively, are given by the extraction ratios Efmig I and Efmig L . For intraduodenal and intravenous doses of M (Dose M ID and Dose M IV ), the amounts of MG in urine and bile for the TM are given by eqs. 3-6:
The ratios of the amounts of MG in urine/bile for intravenous and intraduodenal dosing of M are identical (eqs. 7-8): 
In like fashion, it may be shown that A 
SFM-PBPK
According to the SFM-PBPK model, MG is formed by the intestine and liver during the first-pass effect, but mostly from the liver upon recirculation due to the segregated flow pattern to the enterocyte region (Cong et al., 2000) . With the assumption that circulating levels of M cannot reach the enterocyte region for intestinal metabolism, the amounts of MG detected into urine ðA 
The ratios of the amounts are as follows (eq. 13 and 14): (eq. 14) by
Similarly, the ratios of MG amounts in bile and urine after the same doses of intraduodenal and intravenous dosing of M are as follows (eq. 15 and 16): . For cases in which M from the circulation would enter the intestine via f Q Q I , the true difference would fall in between unity (for the TM) and the theoretical SFM-PBPK estimate from the above example, since MG is able to enter the liver from the circulation and M is shunted away for metabolism by the intestine. These differences are exploited to discriminate between the SFM-PBPK and TM-PBPK models. It is further interesting to note that when there is complete absorption of M and absence of intestinal glucuronidation/ dmd.aspetjournals.org
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Discussion
With recognition that the intestine can significantly reduce the orally or intraduodenally absorbed dose during first-pass metabolism and that differential induction and inhibition patterns of the enzymes and transporters exist (see Pang and Chow, 2012; Chow and Pang, 2013) , much effort is extended to separate the contributions of the intestine and liver in first-pass metabolism. The direct observations on intestinal metabolism could be deciphered for lorcainide metabolism in portacaval shunts in rodents (Gugler et al., 1975; Giacomini et al., 1980; Plänitz, et al., 1985) and midazolam oxidation in anhepatic patients after duodenal and intravenous administrations during transplant surgery (Paine et al., 1996) . Others examined specific gene knockdown of Cyp3a and NADPH-cytochrome P450 reductase within the intestinal versus hepatic tissue to directly demonstrate the effect of the knockdown of intestinal versus liver enzymes in first-pass metabolism in vivo (van Herwaarden et al., 2007; Zhang et al., 2007 Zhang et al., , 2009 . The method of comparison of plasma or blood AUCs of drug after oral, intraportal, and intravenous administration, supplemented by in vitro metabolic data, is commonly used to identify the presence of intestinal and extrahepatic versus liver drug metabolism (Iwamoto and Klaassen, 1977; Iwamoto et al., 1982; Cassidy and Houston, 1984, Mistry and Houston, 1987; Liu et al., 2010) . Judging merely from the AUC of the blood concentration of the MG or formed metabolite, AUC MG , it becomes difficult to tease out each of the individual contributions of the intestine and liver since multiple tissues are involved in the formation and sequential metabolism of the metabolite . The situation becomes more complex for metabolite kinetics when the metabolite formed undergoes sequential elimination (by metabolism or excretion) (Pang and Gillette, 1979) , when a permeability barrier exists (de Lannoy and Pang, 1986) , and when the intestine with segregated flow is involved for metabolite formation (Cong et al., 2000) . The metabolism of M to MG by the intestine and liver and the immediate excretion of MG in the formation organs exemplify this situation.
The inadequacy of the compartmental model is shown readily. The compartmental approach (Fig. 1) overpredicted MG excretion into bile 1132 Yang et al. at ASPET Journals on January 20, 2018 dmd.aspetjournals.org
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for intravenous dosing but underpredicted MG excretion for intraduodenal dosing of M; it also overpredicted MG excretion in urine for intravenous dosing, whereas it underpredicted MG excretion for intraduodenal dosing. The CL tot was 8.8 ml·min 21 (Table 4) Table 4 with Tables 5 and 7) .
By contrast, we obtain much more insight on M and MG handling with TM-and SFM-PBPK modeling. The final model consists of uptake, transport, and metabolic pathways of M and MG (Table 5) ) influx clearances for MG were assigned (Fig. 2) , and sequential removal of MG is via secretion, in contrast with other metabolites that may undergo further metabolism (Pang and Gillette, 1979) . We had tested other PBPK models (CL (Table 7) . Moreover, the estimates of F I and F L that dissect the contribution of the intestine and liver first-pass removal were provided. We emphasize that there are differences in intestinal metabolism when M is entering the intestine from the circulation, and the SFM predicted a smaller intestinal contribution than the TM that during the recirculation of M (Table 7) .
In pursuit of whether the SFM is superior to the TM in describing intestinal metabolism of morphine in vivo, we nested these intestinal models into the PBPK model for data fitting (Fig. 2) . When both the intestine and liver are involved in formation of the metabolite, we illustrate that the metabolic data are best used to provide discrimination between the SFM-PBPK versus the TM-PBPK model. Therefore, we examined the metabolism of M and excretion of MG. M enters cells freely by passive diffusion, whereas the formed metabolite MG is poorly permeable across the intestine and liver basolateral membranes (Doherty van de Wetering et al., 2007) . MG formed in the intestine and liver is effluxed out by Mrp3 or excreted by Mrp2 into the lumen or bile, respectively. The MG in bile originates mostly from M metabolism in liver since little MG formed from intestine entered the liver, with both MG speceis excreted into bile. In contrast, MG in urine originates from both the intestine and liver. Thus, after making some simple assumptions, differences are expected between the SFM-PBPK and TM-PBPK predictions based on our simple mass balance solutions on the ratio, A (Table 3) . These observations agree well with the predicted SFM ratio, being .1 (eq. 16), whereas for TM (eq. 8), the ratio equals 1 (Table 8) . Moreover, the superior fit to the SFM model (Figs. 5 and 6; Table 6), and the simulated patterns for M and MG correlated better with the observed data than TM (Figs. 4-6) , suggesting that the SFM-PBPK describes first-pass removal of M and MG in rats in vivo much better than the TM-PBPK. With these observations, we may conclude that systemically delivered morphine is partially shunted away from reaching the enterocyte region containing Ugt2b1 for glucuronidation.
The question that remains is why there is urgency to identify the proper intestinal model in PBPK modeling. Recent examination of intestinal flow models emphasized that the type of intestinal flow model chosen is important: TM, Q Gut model (Yang et al., 2007) , or SFM, in which the fractional flow to enterocyte region (f Q ) is 1, 0.484, and 0.1-0.3, respectively (Pang and Chow, 2012) . For most substrates, the fitted f Q is , 0.2 (Pang and Chow, 2012; Chow and Pang, 2013) , and it is 0.10 for this study (Table 5) . Since the percent contribution of the intestine during recirculation of M is dependent on f Q (see equations shown as footnotes to Table 7) , we expect the ranking of SFM , Q Gut model , TM to stand, whereas the opposite exists for the percent contribution of liver (SFM . Q Gut model . TM) (Pang and Chow, 2012) . These interpretations could affect the translation of in vitro microsomal activity to the metabolic intrinsic clearance, CL int,met , in vivo. The intestinal flow model chosen to represent the enterocyte flow may also influence values of F I and E I . The data of Mistry and Houston (1987) revealed a 24-fold microsomal activity ratio (CL int,met,L /CL int,met,I ) in vitro; yet in vivo E I and E L values of 0.33 and 0.47, respectively, correlated with only a 37-fold intrinsic clearance ratio (calculated CL int,met,L /CL int,met,I ) in vivo for morphine glucuronidation in the rat. Therefore, the flow pattern to the enterocyte region of the intestine may play a role in altering in vitro-in vivo extrapolation. Pang and Kwan (1983) . b Calculated based on equations from Pang and Chow (2012) :
Calculated based on equations from Pang and Chow (2012) :
Equations from . 
